New hope for lung transplant patients: drug may block dangerous virus
NCT ID NCT05041426
First seen Apr 14, 2026 · Last updated May 24, 2026 · Updated 9 times
Summary
This study tested whether the drug letermovir can prevent CMV infection in adults who received a lung transplant for idiopathic pulmonary fibrosis (IPF). Fifteen participants took letermovir after transplant, and researchers tracked how many developed CMV infection or disease during treatment and for three months after. The goal was to see if letermovir is a safe and effective option for preventing this common post-transplant complication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG TRANSPLANT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UPMC
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.